**Supplementary Tables**

Table (1): Sero-prevalence of Hepatitis A, Hepatitis B, and Hepatitis C in Jordan

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Test | Total Number | Years | Results | Count (N %) |
| HAV-IgM | 5791 | 2017-2022 | Negative | 4696 (81.1%) |
|  |  |  | Positive | 1095 (18.9%) |
| HAV-TAB | 498 | 2018-2022 | Negative | 242 (48.6%) |
|  |  |  | Positive | 256 (51.4%) |
| HBsAg | 20991 | 2017-2022 | Negative | 19863 (94.6%) |
|  |  |  | Positive | 1128 (5.4%) |
| HBsAb | 5771 | 2017-2022 | Negative | 2195 (38.0%) |
|  |  |  | Positive | 3576 (62.0%) |
| HBeAg | 558 | 2017-2022 | Negative | 525 (94.1%) |
|  |  |  | Positive | 33 (5.9%) |
| HBeAb | 407 | 2017-2022 | Negative | 269 (66.1%) |
|  |  |  | Positive | 138 (33.9%) |
| HBcAb-IgM | 478 | 2017-2022 | Negative | 451 (94.4%) |
|  |  |  | Positive | 27 (5.6%) |
| HCV-TAB | 524 | 2017-2022 | Negative | 493 (94.1%) |
|  |  |  | Positive | 31 (5.9%) |

HAV-IgM: Hepatitis A Virus, IgM Antibodies; HAV TAB: Hepatitis A Virus Total Antibodies; HBsAg: Hepatitis B surface Antigen; HBsAb: Hepatitis B surface Antibodies; HBeAg: Hepatitis B envelope Antigen; HBeAb: Hepatitis B envelope Antibodies; HBcAb-IgM: Hepatitis B core IgM Antibodies; HCV TAB: Hepatitis C Virus Total Antibodies.

Table (2) Prevalence of HAV Antibodies - Serological Test Results by Year, Gender, and Age

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| HAV-IgM | Category | Subcategory | Positive Count | N % | Total Count | P Value |
|  | Year | 2017 | 36 | 16.8% | 214 | <0.001\* |
|  |  | 2018 | 276 | 23.1% | 1195 |
|  |  | 2019 | 148 | 14.1% | 1047 |
|  |  | 2020 | 206 | 25.9% | 796 |
|  |  | 2021 | 379 | 31.3% | 1211 |
|  |  | 2022 | 40 | 4.1% | 965 |
|  | Gender | Male | 624 | 19.5% | 3195 | 0.3 |
|  |  | Female | 461 | 20.7% | 2230 |
|  | Age | 20 or less | 590 | 47.0% | 1255 | <0.001\* |
|  |  | 21-40 | 459 | 14.4% | 3191 |
|  |  | 41-60 | 35 | 5.3% | 666 |
|  |  | more than 60 | 1 | 0.3% | 316 |
| HAV-Total Antibodies | **Category** | **Subcategory** | **Positive Count** | **N %** | **Total Count** | **P Value** |
|  | Year | 2018 | 47 | 50.5% | 93 | 0.02\* |
|  |  | 2019 | 59 | 51.8% | 114 |
|  |  | 2020 | 43 | 59.7% | 72 |
|  |  | 2021 | 34 | 36.6% | 93 |
|  |  | 2022 | 73 | 57.9% | 126 |
|  | Gender | Male | 171 | 54.1% | 316 | 0.11 |
|  |  | Female | 85 | 46.7% | 182 |
|  | Age | 20 or less | 27 | 46.6% | 58 | 0.35 |
|  |  | 21-40 | 186 | 51.5% | 361 |
|  |  | 41-60 | 25 | 48.1% | 52 |
|  |  | more than 60 | 18 | 66.7% | 27 |

Table (3) Prevalence of HBV - Serological Test Results by Year, Gender, and Age

Top of Form

Bottom of Form

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| HBsAg | Category | Subcategory | Positive Count | N % | Total Count | P Value |
|  | Year | 2017 | 63 | 4.4% | 1420 | <0.001\* |
|  |  | 2018 | 54 | 3.9% | 1387 |
|  |  | 2019 | 323 | 5.8% | 5570 |
|  |  | 2020 | 185 | 4.8% | 3878 |
|  |  | 2021 | 284 | 6.8% | 4171 |
|  |  | 2022 | 219 | 4.8% | 4565 |
|  | Gender | Male | 741 | 8.5% | 8475 | <0.001\* |
|  |  | Female | 387 | 7.3% | 12514 |
|  | Age | 20 or less | 18 | 8.7% | 949 | <0.001\* |
|  |  | 21-40 | 571 | 3.1% | 13227 |
|  |  | 41-60 | 389 | 1.9% | 4561 |
|  |  | more than 60 | 111 | 4.3% | 1530 |
| HBsAb | **Category** | **Subcategory** | **Positive Count** | **N %** | **Total Count** | **P Value** |
|  | Year | 2017 | 123 | 60.6% | 203 | 0.04\* |
|  |  | 2018 | 605 | 61.2% | 989 |
|  |  | 2019 | 649 | 64.1% | 1013 |
|  |  | 2020 | 483 | 58.5% | 826 |
|  |  | 2021 | 620 | 60.7% | 1021 |
|  |  | 2022 | 801 | 64.8% | 1236 |
|  | Gender | Male | 1351 | 59.4% | 2276 | 0.001\* |
|  |  | Female | 1919 | 64.0% | 2997 |
|  | Age | 20 or less | 253 | 72.1% | 351 | <0.001\* |
|  |  | 21-40 | 2336 | 65.1% | 3586 |
|  |  | 41-60 | 563 | 52.5% | 1072 |
|  |  | more than 60 | 129 | 46.2% | 279 |
| HBeAg | **Category** | **Subcategory** | **Positive Count** | **N %** | **Total Count** | **P Value** |
|  | Year | 2017 | 0 | 0.0% | 19 | 0.9 not applicable |
|  |  | 2018 | 7 | 6.9% | 102 |
|  |  | 2019 | 6 | 5.9% | 102 |
|  |  | 2020 | 5 | 7.4% | 68 |
|  |  | 2021 | 6 | 6.0% | 100 |
|  |  | 2022 | 6 | 5.9% | 106 |
|  | Gender | Male | 22 | 6.9% | 320 | 0.29 |
|  |  | Female | 8 | 4.5% | 178 |
|  | Age | 20 or less | 5 | 23.8% | 21 | Not applicable |
|  |  | 21-40 | 10 | 4.1% | 242 |
|  |  | 41-60 | 11 | 6.3% | 174 |
|  |  | more than 60 | 4 | 6.3% | 63 |
| HBeAb | **Category** | **Subcategory** | **Positive Count** | **N %** | **Total Count** | **P Value** |
|  | Year | 2017 | 17 | 42.5% | 40 | 0.63 |
|  |  | 2018 | 23 | 38.3% | 60 |
|  |  | 2019 | 21 | 28.8% | 73 |
|  |  | 2020 | 17 | 42.5% | 40 |
|  |  | 2021 | 24 | 34.3% | 70 |
|  |  | 2022 | 27 | 33.8% | 80 |
|  | Gender | Male | 91 | 35.4% | 257 | 0.70 |
|  |  | Female | 38 | 33.3% | 114 |
|  | Age | 20 or less | 32 | 80.0% | 40 | <0.001\* |
|  |  | 21-40 | 60 | 37.3% | 161 |
|  |  | 41-60 | 20 | 16.3% | 123 |
|  |  | more than 60 | 17 | 34.7% | 49 |
| HBcAb-IgM | **Category** | **Subcategory** | **Positive Count** | **N %** | **Total Count** | **P Value** |
|  | Year | 2017 | 36 | 16.8% | 214 | <0.001\* |
|  |  | 2018 | 276 | 23.1% | 1195 | - |
|  |  | 2019 | 148 | 14.1% | 1047 | - |
|  |  | 2020 | 206 | 25.9% | 796 | - |
|  |  | 2021 | 379 | 31.3% | 1211 | - |
|  |  | 2022 | 40 | 4.1% | 965 | - |
|  | Gender | Male | 624 | 19.5% | 3195 | 0.3 |
|  |  | Female | 461 | 20.7% | 2230 | - |
|  | Age | 20 or less | 590 | 47.0% | 1255 | <0.001\* |
|  |  | 21-40 | 459 | 14.4% | 3191 | - |
|  |  | 41-60 | 35 | 5.3% | 666 | - |
|  |  | more than 60 | 1 | 0.3% | 316 | - |

Top of Form

Bottom of Form

Table (4) Prevalence of Hepatitis C Virus (HCV) Total Antibodies (2017-2022) - Serological Test Results by Year, Gender, and Age

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Results | Positive | Count | N % | Total Count | P value |
| Year | **2017** | 0 | 0.0% | 37 | 0.002\* |
|  | **2018** | 5 | 3.3% | 151 |  |
|  | **2019** | 17 | 13.5% | 126 |  |
|  | **2020** | 5 | 8.8% | 57 |  |
|  | **2021** | 1 | 1.9% | 53 |  |
|  | **2022** | 3 | 4.2% | 72 |  |
| Gender | **Male** | 17 | 8.1% | 210 | 0.12 |
|  | **Female** | 14 | 4.7% | 296 |  |
| Age | **20 or less** | 0 | 0.0% | 23 | 0.59 |
|  | **21-40** | 12 | 4.2% | 284 |  |
|  | **41-60** | 16 | 9.7% | 165 |  |
|  | **more than 60** | 3 | 8.3% | 36 |  |

\*Note: chi square is inapplicable due to sample size in each group